Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company whose news flow centers on its TGF-ß pathway–focused pipeline, corporate strategy and capital allocation decisions. The company’s disclosures describe a focus on developing protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, with particular emphasis on neuromuscular and hematologic conditions.
News about Keros frequently highlights clinical development milestones for its lead product candidate, KER-065, which is being developed for neuromuscular diseases with an initial focus on Duchenne muscular dystrophy. Recent updates have included Phase 1 clinical data in healthy volunteers, additional analyses of bone and muscle-related endpoints, and U.S. Food and Drug Administration Orphan Drug designation for KER-065 in DMD. Investors following KROS news can expect coverage of trial design, safety and pharmacodynamic findings, and plans for subsequent clinical phases.
Another recurring theme in Keros news is progress related to elritercept, the company’s most advanced product candidate for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis. The company has reported developments under its global license agreement with Takeda Pharmaceuticals U.S.A., Inc., including Takeda’s plans to advance elritercept into a Phase 3 clinical trial in first-line myelodysplastic syndromes.
Keros’ news flow also includes corporate and financial updates. These have covered a strategic realignment to prioritize KER-065, discontinuation of internal development of cibotercept (KER-012), leadership and board changes, and a substantial capital return program involving stock repurchase agreements and a cash tender offer for a significant portion of its outstanding common stock. Earnings releases and Form 8-K filings provide additional context on financial results, cash position and the execution of the capital return plan.
For investors and observers, the KROS news page offers a consolidated view of clinical trial announcements, regulatory designations, partnership developments, governance changes and capital allocation actions that shape the company’s trajectory. Regular review of these updates can help track how Keros advances its TGF-ß–focused pipeline and manages its resources over time.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced promising results from a preclinical study of RKER-012 for pulmonary arterial hypertension (PAH) at the Pulmonary Hypertension Association Conference (June 10-12, 2022). RKER-012, an Activin Receptor Type IIB ligand trap, significantly reduced cardiac and pulmonary pathology in a rodent model, leading to lower Fulton index and systolic pulmonary arterial pressure (sPAP) compared to the control. These results suggest RKER-012 could potentially mitigate PAH-related damage to the heart and lung tissues.
Keros Therapeutics (KROS) announced new data from its ongoing Phase 2 trial of KER-050, targeting myelodysplastic syndromes (MDS), presented at the EHA Congress. The trial showed 51.9% of evaluable patients achieved an overall erythroid response. Part 2 of the trial has begun with a starting dose of 3.75 mg/kg, allowing for escalation to 5.0 mg/kg. KER-050 displayed a favorable safety profile with no serious adverse events reported. Keros also shared preclinical findings on KER-050's potential effects on thrombopoiesis and anemia treatment, suggesting a strong basis for further development.
Keros Therapeutics, Inc. (Nasdaq: KROS) reported preliminary topline results from Part 1 of its Phase 1 clinical trial for KER-012, aimed at treating bone-related disorders. The trial involved 32 healthy postmenopausal subjects receiving varying doses of KER-012. Results indicate KER-012 was generally well tolerated up to the highest tested dose of 5 mg/kg, with no serious adverse events reported. Key findings include a 39.6% reduction in follicle-stimulating hormone after a single high dose and significant increases in bone formation markers. Part 2 is ongoing, with data expected in H2 2022.
Keros Therapeutics (Nasdaq: KROS) announced promising results from a preclinical study of RKER-012 for treating pulmonary arterial hypertension (PAH) at the ATS International Conference. RKER-012 effectively prevented increases in pulmonary arterial pressure and right ventricle hypertrophy in a rodent model. In a separate study, KER-012 did not increase red blood cell levels in cynomolgus monkeys. These findings suggest that KER-012 may offer a safer treatment option for PAH without dose-limiting side effects. The company emphasizes KER-012's potential in treating PAH without adversely affecting red blood cell counts.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced the presentation of three abstracts from its KER-050 and ALK2 hematology programs at the 27th Annual Congress of the European Hematology Association (EHA) from June 9-17, 2022. The abstracts include a Phase 2 study on KER-050 for anemia treatment in myelodysplastic syndromes, along with two preclinical studies related to platelet production and anemia of inflammation. KER-050 aims to address low blood cell counts in patients suffering from significant hematological disorders.
Keros Therapeutics (Nasdaq: KROS) reported a net loss of $24.2 million for Q1 2022, up from $15.9 million in Q1 2021, primarily due to increased research and development and infrastructure costs. R&D expenses rose to $18.1 million compared to $11.5 million last year, while G&A expenses increased to $6.0 million from $4.3 million. The company has cash reserves of $228.6 million, expected to sustain operations through Q1 2024. Keros plans to share data from its Phase 2 trial of KER-050 in mid-2022 and initial results from the Phase 1 trial of KER-012 in Q2 2022.
Keros Therapeutics (KROS) reported its fourth quarter and full year 2021 financial results, highlighting a net loss of $6.9 million for Q4 and $58.7 million for the year, up from a $10.7 million loss in Q4 2020. Total revenue for 2021 was $20.1 million, attributed mainly to its strategic partnership with Hansoh for KER-050 in China, which brought in an $18 million upfront payment. Research and development expenses increased significantly to $18.8 million for Q4 as Keros advances clinical trials for KER-050 and KER-012. The company expects its cash reserves to last into Q1 2024.
Keros Therapeutics, Inc. (NASDAQ: KROS) announced that CEO Jasbir S. Seehra, Ph.D. will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 9:20 am ET. The presentation will be available via live webcast and will be archived on Keros’ investors' page for 90 days post-event. Keros specializes in developing treatments for hematological and musculoskeletal disorders, focusing on unmet medical needs with candidates like KER-050 for cytopenias, KER-047 for iron imbalance-related anemia, and KER-012 for bone loss disorders.
Keros Therapeutics, Inc. (KROS) has appointed Christopher Rovaldi as Chief Operating Officer, effective February 1, 2022. Rovaldi brings over 15 years of experience in developing TGF-β molecules across various diseases. His previous roles include senior leadership positions at Acceleron Pharma, and he has been a consultant since 2018. CEO Jasbir S. Seehra emphasized the importance of Rovaldi's expertise in advancing Keros' pipeline of novel treatments for hematological and musculoskeletal disorders. Keros focuses on addressing high unmet medical needs with its lead candidates KER-050, KER-047, and KER-012.
Keros Therapeutics (Nasdaq: KROS) has re-issued a press release from December 13, 2021, to correct typographical errors regarding its Phase 2 clinical trial of KER-050 for treating anemia in patients with myelodysplastic syndromes (MDS). The corrected document states that two cases of treatment-emergent adverse events, nausea and diarrhea, were related to KER-050. The trial aims to assess KER-050's safety and efficacy in various dosing cohorts, with initial data showing promising erythroid responses in evaluable patients. Keros continues to explore KER-050's potential in MDS and related disorders.